IQVIA Holdings Inc.
IQV evidence brief
What we can confirm
- BioSniper Score:
- 5.2 / 10
- Market Cap:
- $42.67B
- Next Catalyst:
- Earnings · Oct 27, 2026
What it means
What to watch
Prepared research question
What matters most for IQV—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · IQV
IQVIA Holdings Inc. (IQV) is a global provider of clinical research services, commercial insights, and healthcare intelligence, leveraging AI-powered tools and a vast healthcare database to serve life sciences clients.
Key risk: Regulatory threats
BioSniper Score
Based on 4 of 6 signals
Financial data as of Mar 31, 2026.
Tracking 2 catalysts for IQVIA Holdings Inc..
IQVIA Holdings Inc. (IQV) is a global provider of clinical research services, commercial insights, and healthcare intelligence, leveraging AI-powered tools and a vast healthcare database to serve life sciences clients.
- Cash & equivalents of $1,947.0M as of 2026-03-31 [sec]
- Total revenue of $4,151.0M and net income of $274.0M as of 2026-03-31 [sec]
- Shareholders' equity of $6,221.0M as of 2026-03-31 [sec]
- Approximately 94,000 employees in over 100 countries [sec_mda · as of 2026-07-28]
- Launched IQVIA Predictive Clinical Development, an AI-powered approach to reduce avoidable delays and bring therapies to market up to two years faster [news · published 2026-09-03]
What works
- Extensive healthcare database and AI-enabled capabilities support growth and strong R&DS bookings [news · published 2026-10-02]
- IQVIA Predictive Clinical Development aims to bring new therapies to patients up to two years faster, offering significant efficiencies to sponsors [news · published 2026-09-03]
- RBC Capital initiated coverage with an Outperform rating, citing significant progress in clinical trial capabilities [news · published 2026-03-11]
What to weigh
- Low liquidity and $14.1B net debt remain in focus [news · published 2026-10-02]
- Cash balance decreased from $1,980M as of December 31, 2025 to $1,947M as of March 31, 2026 [sec_mda · as of 2026-05-05]
- Rating downgrade due to slowing guidance and regulatory threats [news · published 2026-07-29]
From the filings
Quoted directly from source documents.
Cash position as of March 31, 2026
“We had a cash balance of $1,947 million as of March 31, 2026 ($635 million of which was in the United States), a decrease from $1,980 million as of December 31, 2025.”
SEC MD&A · May 5, 2026
Employee count and global presence
“With approximately 94,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, we are dedicated to accelerating the development and commercialization of in”
SEC MD&A · July 28, 2026
Launch of AI-powered clinical development tool
“IQVIA Predictive Clinical Development, an AI-powered approach designed to help life sciences sponsors reduce avoidable delays and bring new therapies to patients up to two years faster.”
News · September 3, 2026
Net debt and liquidity concerns
“IQV's vast healthcare database, AI-enabled capabilities and strong R&DS bookings support growth, while low liquidity and $14.1B net debt remain in focus.”
News · October 2, 2026
Catalyst timeline
- 2026-10-27 · Earnings: IQVIA to Announce Third-Quarter 2026 Results on October 27, 2026 — IQVIA will release its third-quarter 2026 financial results, providing updated revenue, net income, and cash position.
- 2042-05-27 · Patent_Expiry: NDA213004 — Patent expiry for NDA213004 (AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN), which may affect related product revenues.
Risks & what to watch (4)›
Key risks
- Regulatory threats — Government regulators may impose new regulatory requirements or adopt new regulations affecting the biopharmaceutical industry [sec_mda · as of 2026-07-28]
- Client concentration risk — Risks related to client or therapeutic concentration could impact revenue stability [sec_mda · as of 2026-07-28]
- High net debt — Low liquidity and $14.1B net debt remain in focus [news · published 2026-10-02]
- Currency and exchange rate risk — Risks associated with operating on a global basis, including currency or exchange rate fluctuations [sec_mda · as of 2026-07-28]
What to watch
- Third-quarter 2026 financial results to be announced on October 27, 2026 [catalyst]
- Impact of IQVIA Predictive Clinical Development on client adoption and revenue growth [news · published 2026-09-03]
- Trend in cash balance and net debt levels in upcoming quarterly reports [sec_mda · as of 2026-05-05]
- Regulatory developments affecting the biopharmaceutical industry [sec_mda · as of 2026-07-28]
Sources: Catalysts · Competitor trials · News · SEC MD&A · Generated October 9, 2026 · How we verify sources →
Run IQVIA Holdings Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available IQVIA Holdings Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Profitable (positive operating cash flow)
D/E 3.75 · 1% dilution
No tracked pipeline phase
No tracked pipeline candidates
2 upcoming, next in ~12d
0 buys · 8 sells (180d)
Catalysts
Financials
Short Interest
as of Apr 19, 2026- % of float
- 3.1%
- Days to cover
- 2.8
- Shares short
- 4,514,586
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
IQV short interestGovernance
Frequently asked questions
What is the AI investment thesis for IQVIA Holdings Inc.?
IQVIA Holdings Inc. (IQV) is a global provider of clinical research services, commercial insights, and healthcare intelligence, leveraging AI-powered tools and a vast healthcare database to serve life sciences clients.
What is IQVIA Holdings Inc.'s next catalyst?
IQVIA Holdings Inc.'s next tracked catalyst is a Earnings event — "Earnings: IQVIA to Announce Third-Quarter 2026 Results on October 27, 2026" — expected October 27, 2026.
Who is the CEO of IQVIA Holdings Inc.?
Mr. Ari Bousbib is the chief executive officer of IQVIA Holdings Inc. (IQV).
Where is IQVIA Holdings Inc. headquartered?
IQVIA Holdings Inc. (IQV) is headquartered in Durham, NC, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.